2026 ESMO | FLAURA2最新探索性分析：早期血浆EGFR清除动力学与临床结局的关联_腾讯新闻
前言随着FLAURA2和MARIPOSA等关键III期研究的相继公布，以三代表皮生...
EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing - a case report
BackgroundLeptomeningeal metastasis (LM) is a severe complication of advanced non-small cell lung cancer (NSCLC). Conventional cerebrospinal fluid (CSF) cyto Abstract Background: Leptomeningeal metastasis (LM) is a severe complication of advanced non-small cell lung cancer (NSCLC). Conventional cerebrospinal fluid (CSF) cytology...
Targeting EGFR signaling to reduce mucus overproduction in lung diseases
Chinese Academy of SciencesNov 2 2026 Reviewed Airway mucus is part of innate lung defense, but when production overwhelms clearance, it obstructs airflow and worsens disease. About half of people with chronic obstructive pulmonary disease (COPD) show mucus hypersecretion, and...
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
Published Nov 1, 2026 7:00pm EST - Follows US FDA new drug application submission in September 2026, marking important global regulatory progress - - Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS...
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
HONG KONG and FLORHAM PARK, N.J., Nov. 01, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that regulatory filings for ORPATHYS® (savolitinib) in combination with TAGRISSO® (osimertinib) have been accepted for review in Europe and...
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
- Follows US FDA new drug application submission in September 2026, marking important global regulatory progress - - Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements - - Data...
Hutchmed (00013): Regulatory registration applications for the combination of Orpathys and Tagrisso for the treatment of MET-driven EGFR-mutant lung cancer have been accepted in Europe and Japan.
Hutchmed (00013) announced that the regulatory registration applications for the combination therapy of Vorasidenib (savolitinib) and Tagrisso (osimertinib) have been accepted in Europe and Japan. Zhitong Finance reports that Hutchison China MediTech (00013) announced that the regulatory registration applications for...
Association of early brain radiotherapy with survival outcomes in patients with asymptomatic brain metastases from non-small cell lung cancer treated with third-generation EGFR tyrosine kinase inhibitors: a retrospective single-center study
AbstractObjective To evaluate the association between upfront brain radiotherapy and survival outcomes in patients with asymptomatic brain metastases from non-small cell lung cancer (NSCLC) receiving first-line third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Methods This retrospective, single-center study...
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR
- Follows US FDA new drug application submission in September 2026, marking important global regulatory progress - - Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements - - Data...
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
- Follows US FDA new drug application submission in September 2026, marking important global regulatory progress - - Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements - - Data...